BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33450358)

  • 1. Glutaminase inhibition with telaglenastat (CB-839) improves treatment response in combination with ionizing radiation in head and neck squamous cell carcinoma models.
    Wicker CA; Hunt BG; Krishnan S; Aziz K; Parajuli S; Palackdharry S; Elaban WR; Wise-Draper TM; Mills GB; Waltz SE; Takiar V
    Cancer Lett; 2021 Apr; 502():180-188. PubMed ID: 33450358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.
    Emberley E; Pan A; Chen J; Dang R; Gross M; Huang T; Li W; MacKinnon A; Singh D; Sotirovska N; Steggerda SM; Wang T; Parlati F
    PLoS One; 2021; 16(11):e0259241. PubMed ID: 34731180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutaminase Inhibitors Induce Thiol-Mediated Oxidative Stress and Radiosensitization in Treatment-Resistant Cervical Cancers.
    Rashmi R; Jayachandran K; Zhang J; Menon V; Muhammad N; Zahner M; Ruiz F; Zhang S; Cho K; Wang Y; Huang X; Huang Y; McCormick ML; Rogers BE; Spitz DR; Patti GJ; Schwarz JK
    Mol Cancer Ther; 2020 Dec; 19(12):2465-2475. PubMed ID: 33087507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbonyl reductase 1 is a new target to improve the effect of radiotherapy on head and neck squamous cell carcinoma.
    Yun M; Choi AJ; Lee YC; Kong M; Sung JY; Kim SS; Eun YG
    J Exp Clin Cancer Res; 2018 Oct; 37(1):264. PubMed ID: 30376862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances
    Zeng L; Beggs RR; Cooper TS; Weaver AN; Yang ES
    Mol Cancer Ther; 2017 Apr; 16(4):591-600. PubMed ID: 28138028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHK1/2 Inhibitor Prexasertib Suppresses NOTCH Signaling and Enhances Cytotoxicity of Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma.
    Zeng L; Nikolaev A; Xing C; Della Manna DL; Yang ES
    Mol Cancer Ther; 2020 Jun; 19(6):1279-1288. PubMed ID: 32371584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma.
    Guy JB; Espenel S; Louati S; Gauthier A; Garcia MA; Vial N; Malésys C; Ardail D; Alphonse G; Wozny AS; Rodriguez-Lafrasse C; Magné N
    J Cancer Res Clin Oncol; 2021 Jul; 147(7):1905-1916. PubMed ID: 33791846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy.
    Barker HE; Patel R; McLaughlin M; Schick U; Zaidi S; Nutting CM; Newbold KL; Bhide S; Harrington KJ
    Mol Cancer Ther; 2016 Sep; 15(9):2042-54. PubMed ID: 27422809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
    Momcilovic M; Bailey ST; Lee JT; Fishbein MC; Braas D; Go J; Graeber TG; Parlati F; Demo S; Li R; Walser TC; Gricowski M; Shuman R; Ibarra J; Fridman D; Phelps ME; Badran K; St John M; Bernthal NM; Federman N; Yanagawa J; Dubinett SM; Sadeghi S; Christofk HR; Shackelford DB
    Cancer Cell; 2018 May; 33(5):905-921.e5. PubMed ID: 29763624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A facile and sensitive method of quantifying glutaminase binding to its inhibitor CB-839 in tissues.
    Chen Y; Zhao Y; Bajor DL; Wang Z; Selfridge JE
    J Genet Genomics; 2020 Jul; 47(7):389-395. PubMed ID: 33004309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma.
    Keysar SB; Gomes N; Miller B; Jackson BC; Le PN; Morton JJ; Reisinger J; Chimed TS; Gomez KE; Nieto C; Frederick B; Pronk GJ; Somerset HL; Tan AC; Wang XJ; Raben D; Su TT; Jimeno A
    Cancer Res; 2020 Mar; 80(5):1183-1198. PubMed ID: 31911553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Senescence Induction by Combined Ionizing Radiation and DNA Damage Response Inhibitors in Head and Neck Squamous Cell Carcinoma Cells.
    Dobler C; Jost T; Hecht M; Fietkau R; Distel L
    Cells; 2020 Sep; 9(9):. PubMed ID: 32883016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
    Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenofibrate increases radiosensitivity in head and neck squamous cell carcinoma via inducing G2/M arrest and apoptosis.
    Liu J; Ge YY; Zhu HC; Yang X; Cai J; Zhang C; Lu J; Zhan LL; Qin Q; Yang Y; Yang YH; Zhang H; Chen XC; Liu ZM; Ma JX; Cheng HY; Sun XC
    Asian Pac J Cancer Prev; 2014; 15(16):6649-55. PubMed ID: 25169503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice.
    Boysen G; Jamshidi-Parsian A; Davis MA; Siegel ER; Simecka CM; Kore RA; Dings RPM; Griffin RJ
    Int J Radiat Biol; 2019 Apr; 95(4):436-442. PubMed ID: 30557074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing Metabolic Intervention with a Glutaminase Inhibitor in Real-Time by Hyperpolarized Magnetic Resonance in Acute Myeloid Leukemia.
    Zacharias NM; Baran N; Shanmugavelandy SS; Lee J; Lujan JV; Dutta P; Millward SW; Cai T; Wood CG; Piwnica-Worms D; Konopleva M; Bhattacharya PK
    Mol Cancer Ther; 2019 Nov; 18(11):1937-1946. PubMed ID: 31387889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.
    Shen YA; Hong J; Asaka R; Asaka S; Hsu FC; Suryo Rahmanto Y; Jung JG; Chen YW; Yen TT; Tomaszewski A; Zhang C; Attarwala N; DeMarzo AM; Davidson B; Chuang CM; Chen X; Gaillard S; Le A; Shih IM; Wang TL
    Cancer Res; 2020 Oct; 80(20):4514-4526. PubMed ID: 32859605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
    Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
    Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.